Helus PharmaHELP +7.82%22 Market Cap is $400.29 Mil as of Jun. 28, 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,429 Biotechnology companies, Helus Pharma ranks better than 68.79% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Helus Pharma's share price for the quarter that ended in Dec. 2025 was $8.18. Helus Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 49.89 Mil. Therefore, Helus Pharma's market cap for the quarter that ended in Dec. 2025 was $408.13 Mil.
Helus Pharma's quarterly market cap
declined
from Jun. 2025 ($193.25 Mil) to Sep. 2025 ($153.73 Mil) but then
increased
from Sep. 2025 ($153.73 Mil) to Dec. 2025 ($408.13 Mil).
Helus Pharma's annual market cap
increased
from Mar. 2023 ($75.40 Mil) to Mar. 2024 ($314.29 Mil) but then
declined
from Mar. 2024 ($314.29 Mil) to Mar. 2025 ($137.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Helus Pharma's Enterprise Value for Today is $345.42 Mil.
Helus Pharma (NAS:HELP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Helus Pharma Market Cap Related Terms
Helus Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Helus Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helus Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Helus Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Helus Pharma's Market Cap for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helus Pharma (HELP) has a Market Cap of $400.29 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #446 out of 1429 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Helus Pharma's Market Cap too high?
Helus Pharma's current Market Cap is $400.29 Mil. The Biotechnology industry median Market Cap is 112.70. Helus Pharma's value of $400.29 Mil is 255.2% above this industry median. Based on the distribution chart, Helus Pharma ranks #446 out of 1429 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #446 out of 1429 companies for Market Cap. This puts Helus Pharma in the upper half of its industry. The industry median Market Cap is 112.70. Helus Pharma's value of $400.29 Mil is 255.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helus Pharma's current Market Cap of $400.29 Mil is 255.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helus Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Market Cap is $400.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Market Cap of $400.29 Mil. The current Market Cap is $400.29 Mil and 255.2% above the Biotechnology industry median of 112.70. Helus Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Helus Pharma (HELP), the current Market Cap is $400.29 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score
Get the complete analysis for HELP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HELP has been successfully added to your 
